Preprint · OA
via OpenAlex
Inflammatory Biomarkers as Predictors of Mortality and Persistent Symptoms at Follow-up in Patients with Severe COVID-19
Dominic L. Sykes, Christina Maria Van Der Feltz-Cornelis, Luke Holdsworth, Simon Hart P, Joseph O’Halloran, Stephen Holding, Michael Crooks G
· 2022
Abstract
Background Serum inflammatory biomarkers such as C-reactive protein (CRP) are an established tool for predicting mortality in COVID-19 patients. Data have also suggested that such biomarkers are persistently elevated in patients with Long-COVID. In this study we aimed to assess the relationship between a panel of serum biomarkers (CRP, IL-6, troponin-T, and ferritin), inpatient mortality, and persistent symptoms post-discharge in COVID-19 survivors. Methods Data were collected retrospectively for all patients with COVID-19 admitted between 1st September 2020 and 10th January 2021. Admission CRP, IL-6, ferritin, and troponin-T were collected alongside routinely collected clinical data. A standardised dataset was collected for survivors when they attended clinical follow-up with the local post-hospitalisation COVID-19 follow-up service. Results A total of 626 patients (mean age 70.1 [SD=15.8], 55% male) had all biomarkers recorded. The overall mortality rate in this cohort was 28.4%. Higher levels of IL-6 (p<0.001) and troponin-T (p<0.001) were associated with a significantly higher risk of inpatient mortality. A total of 144 patients received 3-month follow-up, the commonest reported symptoms were fatigue (54.2%), breathlessness (52.8%), and sleep disturbance (37.5%). Patients who reported myalgia, low mood, and anxiety were found to have lower median levels of IL-6, CRP, and ferritin, respectively. Conclusions Raised levels of IL-6 and TT on admission are associated with a significantly increased risk of inpatient mortality in those hospitalised with COVID-19, however, raised inflammatory markers at the time of hospital admission show no association with residual symptom burden at 3-month follow-up in surviving patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.22541/au.167187484.48355876/v1
- Canonical
- link ↗
- Fetched
- 2026-10-15 MST
Cite this
APA
Sykes, D.L., Feltz-Cornelis, C.M.V.D., Holdsworth, L., P, S.H., O’Halloran, J., Holding, S., & G, M.C. (2022). Inflammatory Biomarkers as Predictors of Mortality and Persistent Symptoms at Follow-up in Patients with Severe COVID-19. https://doi.org/10.22541/au.167187484.48355876/v1
Vancouver
Sykes DL, Feltz-Cornelis CMVD, Holdsworth L, P SH, O’Halloran J, Holding S, et al. Inflammatory Biomarkers as Predictors of Mortality and Persistent Symptoms at Follow-up in Patients with Severe COVID-19. 2022. doi:10.22541/au.167187484.48355876/v1.
BibTeX
@unpublished{dominic2022Inflam,
title = {Inflammatory Biomarkers as Predictors of Mortality and Persistent Symptoms at Follow-up in Patients with Severe COVID-19},
author = {Dominic L. Sykes and Christina Maria Van Der Feltz-Cornelis and Luke Holdsworth and Simon Hart P and Joseph O’Halloran and Stephen Holding and Michael Crooks G},
year = {2022},
doi = {10.22541/au.167187484.48355876/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
2022
Citation only
S45 Inflammatory biomarkers as predictors of mortality and persistent symptoms at follow-up in patients with severe COVID-19
Immunity Inflammation and Disease 2023
Open access · CC-BY
Examining the relationship between inflammatory biomarkers during COVID‐19 hospitalization and subsequent long‐COVID symptoms: A longitudinal and retrospective study
Clinical Laboratory 2023
Citation only
Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19
BMC Oral Health 2021
Open access · CC-BY
Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
Journal of Fatima Jinnah Medical University 2022
Open access · CC-BY
Correlation of inflammatory biomarkers with disease severity in hospitalised patients of COVID-19 at presentation
Nephrology Dialysis Transplantation 2011
Citation only